To test this, we depleted SAMHD1 using VLP(+Vpx) and assessed LN-229 and U-87 sensitivity to ABT888 (veliparib), a well-studied PARPi that has been investigated as a potential therapeutic agent for GBM [39]. Here, SAMHD1 is linked to glioblastoma.